Avita

Tretinoin


Mylan Pharmaceuticals Inc.
Human Prescription Drug
NDC 0378-6140
Avita also known as Tretinoin is a human prescription drug labeled by 'Mylan Pharmaceuticals Inc.'. National Drug Code (NDC) number for Avita is 0378-6140. This drug is available in dosage form of Gel. The names of the active, medicinal ingredients in Avita drug includes Tretinoin - .25 mg/g . The currest status of Avita drug is Active.

Drug Information:

Drug NDC: 0378-6140
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Avita
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Tretinoin
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Mylan Pharmaceuticals Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Gel
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:TRETINOIN - .25 mg/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: NDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 18 Mar, 1998
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 31 May, 2023
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: NDA020400
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 02 Jan, 2026
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Mylan Pharmaceuticals Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:208332
313451
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:N0000175607
M0018962
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:5688UTC01R
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Retinoid [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class CS:Retinoids [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Retinoid [EPC]
Retinoids [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0378-6140-4420 g in 1 TUBE (0378-6140-44)18 Mar, 199831 May, 2023No
0378-6140-4545 g in 1 TUBE (0378-6140-45)18 Mar, 199831 May, 2023No
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Avita tretinoin tretinoin tretinoin butylated hydroxytoluene hydroxypropyl cellulose, unspecified

Drug Interactions:

Drug interactions concomitant topical medication, medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime should be used with caution because of possible interaction with tretinoin. particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid with avita ® gel. it also is advisable to “rest” a patient’s skin until the effects of such preparations subside before use of avita ® gel is begun.

Indications and Usage:

Indications and usage avita ® gel is indicated for topical application in the treatment of acne vulgaris. the safety and efficacy of this product in the treatment of other disorders have not been established.

Warnings:

Warnings gels are flammable. note: keep away from heat and flame. keep tube tightly closed.

General Precautions:

General if a reaction suggesting sensitivity or chemical irritation occurs, use of the medication should be discontinued. exposure to sunlight, including sunlamps or artificial sunlight should be minimized during the use of avita ® gel, and patients with sunburn should be advised not to use the product until fully recovered because of heightened susceptibility to sunlight as a result of the use of tretinoin. patients who may be required to have considerable sun exposure due to occupation and those with inherent sensitivity to the sun should exercise particular caution. use of sunscreen products and protective clothing over treated areas is recommended when exposure cannot be avoided. weather extremes, such as wind or cold, also may be irritating to patients under treatment with tretinoin. avita ® (tretinoin gel) gel, 0.025% should be kept away from the eyes, the mouth, the paranasal creases, and mucous membranes.topical use may induce severe local erythema and peeling at the site
of application. if the degree of local irritation warrants, patients should be directed to temporarily use the medication less frequently, discontinue use temporarily, or discontinue use altogether. efficacy at reduced frequencies of application has not been established. tretinoin has been reported to cause severe irritation on eczematous skin and should be used with utmost caution in patients with this condition.

Dosage and Administration:

Dosage and administration avita ® gel should be applied once a day, in the evening, to the skin where acne lesions appear, using enough to cover the entire affected area lightly. application may cause a transient feeling of warmth or slight stinging. in cases where it has been necessary to temporarily discontinue therapy or reduce the frequency of application, therapy may be resumed or frequency of application increased when the patients become able to tolerate the treatment. alterations of dose frequency should be closely monitored by careful observation of the clinical therapeutic response and skin tolerance. efficacy has not been established for less than once-daily dosing frequencies. during the early weeks of therapy, an apparent increase in number and exacerbation of inflammatory acne lesions may occur. this is due, in part, to the action of the medication on deep, previously unseen lesions and should not be considered a reason to discontinue therapy. therapeutic results shoul
d be noticed after two to three weeks, but more than six weeks of therapy may be required before definite beneficial effects are seen. patients treated with avita ® gel may use cosmetics, but the areas to be treated should be cleansed thoroughly before the medication is applied (see precautions section).

Contraindications:

Contraindications the product should not be used if there is hypersensitivity to any of the ingredients.

Adverse Reactions:

Adverse reactions the skin of certain sensitive individuals may become excessively red, edematous, blistered, or crusted. if these effects occur, the medication should either be discontinued until the integrity of the skin is restored, or the medication dosing frequency should be adjusted temporarily to a level the patient can tolerate. however, efficacy has not been established for lower dosing frequencies. true contact allergy to topical tretinoin is rarely encountered.temporary hyper- or hypopigmentation has been reported with repeated application of avita ® gel. some individuals have been reported to have heightened susceptibility to sunlight while under treatment with avita ® gel. adverse effects of avita ® gel have been reversible upon discontinuation of therapy (see dosage and administration section).

Drug Interactions:

Drug interactions concomitant topical medication, medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime should be used with caution because of possible interaction with tretinoin. particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid with avita ® gel. it also is advisable to “rest” a patient’s skin until the effects of such preparations subside before use of avita ® gel is begun.

Use in Pregnancy:

Pregnancy

Overdosage:

Overdosage if medication is applied excessively, no more rapid or better results will be obtained and marked redness, peeling, or discomfort may occur. oral ingestion of the drug may lead to the same side effects as those associated with excessive oral intake of vitamin a.

Description:

Description avita ® gel, a topical retinoid, contains tretinoin 0.025% by weight in a gel vehicle of butylated hydroxytoluene, hydroxypropyl cellulose, polyolprepolymer-2, and ethanol (denatured with tert -butyl alcohol and brucine sulfate) 83% w/w. chemically, tretinoin is all- trans -retinoic acid (c 20 h 28 o 2 ; molecular weight 300.44 vitamin a acid) and has the following structural formula: avita gel structural formula

Clinical Pharmacology:

Clinical pharmacology although the exact mode of action of tretinoin is unknown, current evidence suggests that topical tretinoin decreases cohesiveness of follicular epithelial cells with decreased microcomedo formation. additionally, tretinoin stimulates mitotic activity and increased turnover of follicular epithelial cells causing extrusion of the comedones. pharmacokinetics in vitro and in vivo pharmacokinetic studies with avita ® gel indicate that less than 0.3% of the topically applied dose is bioavailable. circulating plasma levels of both tretinoin and isotretinoin are only slightly elevated above those found in healthy normal controls. clinical studies in two large vehicle-controlled clinical trials, avita ® (tretinoin gel) gel 0.025%, applied once daily was more effective than vehicle in the treatment of facial acne vulgaris of mild to moderate severity . percent reductions in lesion counts after treatment for 12 weeks in these studies are shown in the following tables:
study 1 avita ® gel, 0.025% vehicle gel n = 198 n = 204 noninflammatory lesions -36% -27% inflammatory lesions -35% -25% total lesions -36% -27% study 2 avita ® gel, 0.025% vehicle gel n = 58 n = 58 n = number of subjects noninflammatory lesions -42% -26% inflammatory lesions -38% -23% total lesions -41% -26%

Pharmacokinetics:

Pharmacokinetics in vitro and in vivo pharmacokinetic studies with avita ® gel indicate that less than 0.3% of the topically applied dose is bioavailable. circulating plasma levels of both tretinoin and isotretinoin are only slightly elevated above those found in healthy normal controls.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis and impairment of fertility in a dermal mouse carcinogenicity study with avita® gel, tretinoin was administered to cd-1 mice at topical doses of 0.027 mg/kg (0.003% gel), 0.072 mg/kg (0.008% gel), and 0.225 mg/kg (0.025% gel) for 2 years (5 doses/week). no drug-related tumors were noted in this mouse carcinogenicity study up to the highest dose evaluated in this study of 0.225 mg/kg in both male and female mice, which was 2.6 times the recommended human topical clinical dose (based on weekly dose bsa comparison). for purposes of comparisons of the animal exposure to human exposure, the “recommended human topical clinical dose” is defined as 1.0 g of 0.025% avita® gel applied daily to a 50 kg person. in a chronic, two-year bioassay of vitamin a acid in mice performed by tsubura and yamamoto, generalized amyloid deposition was reported in all vitamin a treated groups in the basal layer of the skin. in cd-1 mice, a similar study reported hyalini
zation at the treated skin sites and the incidence of this finding was 0/50, 3/50, 3/50, and 2/50 in male mice and 1/50, 0/50, 4/50, and 2/50 in female mice from the vehicle control, 0.25 mg/kg, 0.5 mg/kg, and 1 mg/kg groups, respectively. studies in hairless albino mice suggest that tretinoin may enhance the tumorigenic potential of carcinogenic doses of uva and uvb light from a solar simulator. in other studies, when lightly pigmented hairless mice treated with tretinoin were exposed to carcinogenic doses of uva/uvb light, the incidence and rate of development of skin tumors were either reduced or no effect was seen. due to significantly different experimental conditions, no strict comparison of these disparate data is possible at this time. although the significance of these studies to humans is not clear, patients should minimize exposure to sun. the mutagenic potential of tretinoin was evaluated in the ames assay and in the in vivo mouse micronucleus assay, both of which were negative. dermal segment i and iii studies with avita ® gel have not been performed in any species. in oral segment i and segment iii studies in rats with tretinoin, decreased survival of neonates and growth retardation were observed at doses in excess of 2 mg/kg/day (> 400 times the average recommended human topical clinical dose).

Clinical Studies:

Clinical studies in two large vehicle-controlled clinical trials, avita ® (tretinoin gel) gel 0.025%, applied once daily was more effective than vehicle in the treatment of facial acne vulgaris of mild to moderate severity . percent reductions in lesion counts after treatment for 12 weeks in these studies are shown in the following tables: study 1 avita ® gel, 0.025% vehicle gel n = 198 n = 204 noninflammatory lesions -36% -27% inflammatory lesions -35% -25% total lesions -36% -27% study 2 avita ® gel, 0.025% vehicle gel n = 58 n = 58 n = number of subjects noninflammatory lesions -42% -26% inflammatory lesions -38% -23% total lesions -41% -26%

How Supplied:

How supplied avita ® (tretinoin gel) gel, 0.025% is supplied as: ndc code strength quantity 0378-6140-44 0.025% 20 g 0378-6140-45 0.025% 45 g storage conditions: store below 30°c (86°f). avoid freezing. keep this and all medications out of the reach of children. rx only manufactured for: mylan pharmaceuticals inc. morgantown, wv 26505 u.s.a. revised: 1/2018 022.7 avitagl:r7 remove this portion before dispensing

Information for Patients:

Information for patients see attached patient package insert .

Spl Patient Package Insert:

Avita ® (tretinoin gel) gel, 0.025% patient instructions acne treatment important read directions carefully before using this leaflet tells you about avita ® (tretinoin) gel acne treatment as prescribed by your physician. this product is to be used only according to your doctor’s instructions, and it should not be applied to other areas of the body or to other growths or lesions. the safety and effectiveness of this product in other disorders have not been evaluated. if you have any questions, be sure to ask your doctor. warnings gels are flammable. note: keep away from heat and flame. keep tube tightly closed. precautions the effects of the sun on your skin: as you know, overexposure to natural sunlight or the artificial sunlight of a sunlamp can cause sunburn. overexposure to the sun over many years may cause premature aging of the skin and even skin cancer.the chances of these effects occurring will vary depending on skin type, the climate and the care taken to avoid over
exposure to the sun. therapy with avita ® gel may make your skin more susceptible to sunburn and other adverse effects of the sun, so unprotected exposure to natural or artificial sunlight should be minimized. laboratory findings: when laboratory mice are exposed to artificial sunlight, they often develop skin tumors. these sunlight-induced tumors may appear more quickly and in greater number if the mouse is also topically treated with the active ingredient in avita ® gel, tretinoin. in some studies, under different conditions, however, when mice treated with tretinoin were exposed to artificial sunlight, the incidence and rate of development of skin tumors was reduced. there is no evidence to date that tretinoin alone will cause the development of skin tumors in either laboratory animals or humans. use caution in the sun: when outside, even on hazy days, areas treated with avita ® gel should be protected. an effective sunscreen should be used any time you are outside (consult your physician for a recommendation of an spf level which will provide you with the necessary high level of protection). for extended sun exposure, protective clothing, like a hat, should be worn. do not use artificial sunlamps or artificial sunlight while you are using avita ® (tretinoin gel) gel, 0.025%. if you do become sunburned, stop your therapy with avita ® gel until your skin has recovered. avoid excessive exposure to wind or cold: extremes of climate tend to dry or burn normal skin. skin treated with avita ® gel may be more vulnerable to these extremes.your physician can recommend ways to manage your acne treatment under such conditions. possible problems: the skin of certain sensitive individuals may become excessively red, swollen, blistered, or crusted. if you are experiencing severe or persistent irritation, discontinue the use of avita ® gel and consult your physician. there have been reports that, in some patients, areas treated with avita ® gel developed a temporary increase or decrease in the amount of skin pigment (color) present. use other medication only on your physician’s advice: only your physician knows which other medications may be helpful during treatment and will recommend them to you if necessary. follow the physician’s instructions carefully. in addition, you should avoid preparations that may dry or irritate your skin. these preparations may include certain astringents, toiletries containing alcohol, spices or lime, or certain medicated soaps, shampoos, and hair permanent solutions. do not allow anyone else to use this medication. do not use other medications with avita ® gel which are not recommended by your doctor. the medications you have used in the past might cause unnecessary redness or peeling. if you are pregnant, think you are pregnant, or are nursing an infant: no studies have been conducted in humans to establish the safety of avita ® gel in pregnant women. if you are pregnant, think you are pregnant, or are nursing a baby, consult your physician before using this medication. and while you’re on avita ® therapy use a mild non-medicated soap. avoid frequent washings and harsh scrubbing. acne isn’t caused by dirt, so no matter how hard you scrub, you can’t wash it away. washing too frequently or scrubbing too roughly may at times actually make your acne worse. wash your skin gently with a mild, bland soap. two or three times a day should be sufficient. pat skin dry with a towel. let the face dry 20 to 30 minutes before applying avita ® (tretinoin gel) gel, 0.025%. remember, excessive irritation such as rubbing, too much washing, use of other medications not suggested by your physician, etc., may worsen your acne. how to use avita ® (tretinoin) gel to get the best results with avita ® gel therapy, it is necessary to use it properly. forget about the instructions given for other products and the advice of friends. just stick to the special plan your doctor has laid out for you and be patient. remember, when avita ® gel is used properly, many users see improvement by 12 weeks. again, follow instructions - be patient – don’t start and stop therapy on your own - if you have questions, ask your doctor. to help you use the medication correctly, keep these simple instructions in mind. • avita ® gel should be applied once a day, in the evening, or as directed by your physician, to the skin where acne lesions appear, using enough to cover the entire affected area lightly. first, wash with a mild soap and dry your skin gently. wait 20 to 30 minutes before applying medication; it is important for skin to be completely dry in order to minimize possible irritation. • it is better not to use more than the amount suggested by your physician or to apply more frequently than instructed. too much may irritate the skin, waste medication, and won’t give faster or better results. • keep the medication away from the corners of the nose, mouth, eyes, and open wounds. spread away from these areas when applying. • gel: squeeze about a half inch or less of medication onto the fingertip. while that should be enough for your whole face, after you have had some experience with the medication you may find you need slightly more or less to do the job. the medication should become invisible almost immediately. if it is still visible, or if dry flaking occurs from the gel within a minute or so you are using too much. cover the affected area lightly with avita ® gel by first dabbing it on your forehead, chin, and both cheeks, then spreading it over the entire affected area. smooth gently into the skin. • if needed, you may apply a moisturizer or a moisturizer with sunscreen that will not aggravate your acne (noncomedogenic) in the morning after you wash. what to expect with your new treatment avita ® (tretinoin gel) gel, 0.025% works deep inside your skin and this takes time. you cannot make avita ® gel work any faster by applying more than one dose each day, but an excess amount of avita ® gel may irritate your skin. be patient. there may be some discomfort or peeling during the early days of treatment. some patients also notice that their skin begins to take on a blush. these reactions do not happen to everyone. if they do, it is just your skin adjusting to avita ® gel and this usually subsides within two to four weeks. these reactions can usually be minimized by following instructions carefully. should the effects become excessively troublesome, consult your doctor. by three to six weeks, some patients notice an appearance of new blemishes (papules and pustules). at this stage it is important to continue using avita ® gel. if avita ® gel is going to have a beneficial effect for you, you should notice an improvement in your appearance by 6 to 12 weeks of therapy. don’t be discouraged if you see no immediate improvement. don’t stop treatment at the first signs of improvement. once your acne is under control, you should continue regular application of avita ® gel until your physician instructs otherwise. call your doctor for medical advice about side effects. you may report side effects to fda at 1-800-fda-1088. manufactured for: mylan pharmaceuticals inc. morgantown, wv 26505 u.s.a. revised: 1/2018 022.7pl printed in u.s.a.

Package Label Principal Display Panel:

Principal display panel - 0.025% rx only ndc 0378-6140-44 avita ® (tretinoin) gel 0.025% 20 g for topical use only contains: tretinoin 0.025% in a gel vehicle of butylated hydroxytoluene, hydroxypropyl cellulose, polyolprepolymer-2, ethanol (denatured with tertbutyl alcohol and brucine sulfate) 83% w/w. usual dosage: see accompanying package insert for full prescribing information. keep this and all medications out of the reach of children. store below 30°c (86°f). avoid freezing. see end flap for lot number and expiration date. manufactured for: mylan pharmaceuticals inc. morgantown, wv 26505 u.s.a. mylan.com mi:6140:45:1c:r6 551.6 avita gel 0.025% carton label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.